Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sublingual Riluzole for Public Speaking Anxiety in Social Anxiety Disorder
NCT03017508Phase 3Completed
- Sponsor
- Yale University
- Start
- Jan 2017
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of riluzole in Social Anxiety Disorder (SAD) (2 arms), sponsored by Yale University. Primary endpoint: Visual Analog Scale for Anxiety. Started Jan 2017; status: completed.
02
Drugs
riluzole
03
Conditions
Social Anxiety Disorder (SAD)
Beyond the preview
Go deeper on NCT03017508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03017508.